Curasight Future Growth

Future criteria checks 2/6

Curasight is forecast to grow revenue at 97.5% per annum.

Key information

n/a

Earnings growth rate

n/a

EPS growth rate

Biotechs earnings growth	48.4%
Revenue growth rate	97.5%
Future return on equity	n/a
Analyst coverage	Low
Last updated	26 Aug 2024

Recent future growth updates

No updates

Recent updates

Curasight (NGM:CURAS) Is Making Moderate Use Of Debt

Aug 29

Earnings and Revenue Growth Forecasts

NGM:CURAS - Analysts future estimates and past financials data (DKK Millions)
Date	Revenue	Earnings	Free Cash Flow	Cash from Op	Avg. No. Analysts
12/31/2026	66	N/A	N/A	N/A	1
12/31/2025	40	N/A	N/A	N/A	1
12/31/2024	7	N/A	N/A	N/A	1
6/30/2024	N/A	-32	-34	-34	N/A
3/31/2024	N/A	-29	-32	-32	N/A
12/31/2023	N/A	-26	-30	-30	N/A
9/30/2023	N/A	-27	-28	-28	N/A
6/30/2023	N/A	-25	-28	-28	N/A
3/31/2023	N/A	-19	-19	-19	N/A
12/31/2022	N/A	-18	-24	-16	N/A
9/30/2022	N/A	-15	-24	-15	N/A
6/30/2022	N/A	-13	-22	-12	N/A
3/31/2022	N/A	-11	-20	-10	N/A
12/31/2021	N/A	-8	-10	-7	N/A
9/30/2021	N/A	-7	-14	-9	N/A
6/30/2021	N/A	-7	-13	-8	N/A
3/31/2021	N/A	-6	-12	-7	N/A
12/31/2020	N/A	-6	-12	-7	N/A
12/31/2019	N/A	-1	-2	-1	N/A
12/31/2015	N/A	-1	N/A	N/A	N/A

Analyst Future Growth Forecasts

Earnings vs Savings Rate: Insufficient data to determine if CURAS's forecast earnings growth is above the savings rate (1.1%).

Earnings vs Market: Insufficient data to determine if CURAS's earnings are forecast to grow faster than the Swedish market

High Growth Earnings: Insufficient data to determine if CURAS's earnings are expected to grow significantly over the next 3 years.

Revenue vs Market: CURAS's revenue (97.5% per year) is forecast to grow faster than the Swedish market (0.01% per year).

High Growth Revenue: CURAS's revenue (97.5% per year) is forecast to grow faster than 20% per year.

Earnings per Share Growth Forecasts

Future Return on Equity

Future ROE: Insufficient data to determine if CURAS's Return on Equity is forecast to be high in 3 years time

Curasight Future Growth

Future criteria checks 2/6

Key information

Recent future growth updates

Recent updates

New major risk - Financial position

Curasight A/S to Report Q3, 2024 Results on Nov 21, 2024

Curasight (NGM:CURAS) Is Making Moderate Use Of Debt

New minor risk - Shareholder dilution

Curasight A/S to Report Q2, 2024 Results on Aug 22, 2024

Curasight A/S to Report Q3, 2024 Results on Jul 02, 2024

New major risk - Share price stability

New major risk - Financial position

Curasight A/S to Report Q1, 2024 Results on May 23, 2024

Less than half of directors are independent

Curasight A/S Announces Approval of Clinical Trial Application (CTA) for Phase 2 Trial with uTRACE in Prostate Cancer Patients

Curasight A/S Announces Board Changes

Curasight A/S has withdrawn its Follow-on Equity Offering in the amount of SEK 51.155712 million.

Curasight A/S, Annual General Meeting, Mar 21, 2024

Curasight A/S has filed a Follow-on Equity Offering in the amount of SEK 51.155712 million.

Curasight A/S to Report Fiscal Year 2023 Results on Feb 22, 2024

Curasight Gears Up for Phase II Study in Prostate Cancer

Curasight A/S to Report Q3, 2023 Results on Nov 24, 2023

New minor risk - Share price stability

Curasight A/S Reports Positive Preclinical Results with uTREAT[®] in lung cancer (NSCLC)

Curasight A/S Announces Positive Results from the Phase II Study of uTRACE in Brain Cancer Presented at the World Molecular Imaging Congress (WMIC) 2023 in Prague

Curasight A/S to Report Q2, 2023 Results on Aug 24, 2023

Curasight A/S Announces Positive Results in Upar-Pet/MR Phase II Study in Brain Cancer

Curasight A/S Reports Positive Preclinical Results with uTREAT in Aggressive Brain Cancer (Glioblastoma)

Curasight A/S to Report Fiscal Year 2022 Results on Feb 23, 2023

Curasight A/S Initiates Pre-Clinical Studies with uTREAT Therapy in Head and Neck Cancer and Neuroendocrine Tumors

Curasight A/S Announces Recruitment Completes in uPAR-PET Study in Brain Cancer

Curasight A/S, Annual General Meeting, Mar 24, 2022

Curasight A/S Announces Positive Data of uTREAT® in Glioblastoma Provides "Green Light" to Proceed with Next Steps

New 90-day high: kr.41.50

New 90-day high: kr.34.45

Curasight Announces Results from Phase II Study in Prostate Cancer to Be Published in the Journal of Nuclear Medicine

Curasight A/S to Report Q1, 2021 Results on May 20, 2021

Curasight A/S Initiates Pre-Clinical Study on Therapy in Brain Cancer and Signs CRO-Agreement

Curasight A/S has completed an IPO in the amount of DKK 32.688 million.

Earnings and Revenue Growth Forecasts

Analyst Future Growth Forecasts

Earnings per Share Growth Forecasts

Future Return on Equity

Discover growth companies